Unlock instant, AI-driven research and patent intelligence for your innovation.

Novel inhibitors of angiogenesis and tumor growth

an angiogenesis and tumor technology, applied in the direction of angiogenin, drug composition, aerosol delivery, etc., can solve the problem that most chemotherapeutic agents are universally harmful to all dividing cells, and achieve the effect of treating or preventing undeired angiogenesis

Inactive Publication Date: 2008-10-02
UNIV OF SOUTHERN CALIFORNIA
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention is about a protein called Saposin B, which has been found to have anti-angiogenic and anti-tumoral activity. The patent describes isolated polypeptides that are smaller than the full-length protein and can still have the same activity. These polypeptides can be used as anti-angiogenic and anti-tumoral agents in humans. The patent also describes a receptor that specifically binds to Saposin B and is found on the surface of cells. The invention provides a method for treating mammals with pathological conditions associated with undesired angiogenesis by administering the isolated polypeptides.

Problems solved by technology

However, most chemotherapeutic agents are universally harmful to all dividing cells; cancerous or not.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel inhibitors of angiogenesis and tumor growth
  • Novel inhibitors of angiogenesis and tumor growth
  • Novel inhibitors of angiogenesis and tumor growth

Examples

Experimental program
Comparison scheme
Effect test

example 1

Activity of Recombinant Saposin B and Other Prosaposin Chains

[0194]In order to determine whether recombinant Saposin B has anti-angiogenic activity, the coding region of each of the Prosaposin chains was amplified from fibroblast cell lines and cloned into both bacterial (pGEX-KG) and eukaryotic (pcDNA 3.1His A) expression vectors.

[0195]A Ti fibroblast cell line (ATCC, Rockville, Md.) was grown in DMEM media containing 10% FBS. Total RNA was extracted from 4×106 cells by RNAzol reagent (Tel-Test, Friendswood, Tex.). About 5 μg of total RNA was used to synthesize cDNA (Life technologies, Gaithersburg, Md.) using either oligo dT or random primers. To amplify, Saposin B cDNA, two primers were synthesized to correspond to the 5′ and 3′ ends of the coding region (ATT CGA ATT CAA GGG GAC GTT TGC CAG GAC TGC (SEQ ID NO:3) and TTC TGT GAT GAG GTG AAA TAG CTC GAG CTC GAG (SEQ ID NO:4)). The primers were designed so that an Eco RI restriction site was located at the 5′ end and a Xho I restric...

example 2

Saposin B Inhibits Endothelial Cell Migration

[0199]Angiogenesis is mediated by complex biochemical processes including degradation of the basement membrane under existing blood vessel endothelial cells, followed by proliferation and migration of endothelial cells, followed by formation of capillary loops, and recruitment of vascular smooth muscle cells to encase the newly formed vessels and provide stability. KS and endothelial cell migration in the presence of Saposin B was studied in transwell culture plates with 8 μm pore membranes (Costar, Cambridge, Mass.).

[0200]Briefly, wells were coated with fibronectin (25 μg / mL) overnight, and endothelial cells or KS cells were plated in the upper chamber with 100 μL of DMEM / 0.4% FCS. 500 μL of DMEM / 0.4% FCS was added to the lower chamber and incubated at 37° C. for one hour. The test polypeptides, at various concentrations, were added to the upper chamber, and chemotactic agents (VEGF or bFGF at 20 ng / mL) were added to the lower cell-cultu...

example 3

Saposin B Inhibits Angiogenesis in CAM Assays

[0203]In order to test anti-angiogenic activity, chicken allantoic membrane (CAM) assays were performed with recombinant Saposin B. Ten day old fertilized chicken eggs were prepared for assay by creating a window in the egg shell, and placing filter paper discs saturated with VEGF or bFGF as positive controls, test compounds, or carrier buffer (negative controls) on the allantoic membrane. The membranes were harvested after 48 hours and analyzed using an Olympus stereomicroscope. The number of branching blood vessels that infiltrated under the discs were counted and photographed. Eight CAMs were studied for test group, and the experiments were repeated at least twice.

[0204]Recombinant Saposin B effectively blocked angiogenesis induced by VEGF or bFGF. See FIG. 3. Moreover, the inhibition of angiogenesis induced by both proteins was blocked by adding anti-Saposin B antibodies to the filter paper. These results demonstrate that Saposin B ha...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Tmaaaaaaaaaa
TMaaaaaaaaaa
TMaaaaaaaaaa
Login to View More

Abstract

This invention provides for polypeptides that have surprising anti-angiogenic activity. These peptides are derived from Saposin B, a previously known protein involved in the hydrolysis of sphingolipids. In addition, methods of treating mammals with these anti-angiogenic polypeptides are provided, as well as the pharmaceutical compositions used to treat. Furthermore, the polypeptides of this invention can be used in fusion proteins, wherein the fusion proteins also comprise cell targeting or cytotoxic moieties. Also provided is the receptor to which these polypeptides bind.

Description

CROSS-REFERENCES TO RELATED APPLICATIONS[0001]This application is a continuation in part of U.S. Provisional Application 60 / 092,647, filed Jul. 13, 1998, which is incorporated by reference in its entirety.STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT[0002]Not Applicable.BACKGROUND OF THE INVENTION[0003]Angiogenesis is the formation of new blood vessels from existing blood vessels. To initiate the angiogenic process, biochemical signals stimulate protease secretion from, among other cell types, endothelial cells lining the lumen of the vessel. The secreted proteases degrade the basement membrane and the endothelial cell layer protrudes through the hole created in the basement membrane. If the biochemical signals are continuously present, the migrating endothelial cells undergo mitosis and divide. The dividing cells form a sprout through the vessel wall. Again, if the angiogenic stimulus remains, the sprouts merge to form capillary loops ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/00C07K14/00C12N15/09A61K9/06A61K9/08A61K38/00A61P9/00A61P35/00A61P43/00C07K4/00C07K4/12C07K14/21C07K14/47C07K14/475C07K14/515C07K16/18C07K19/00
CPCA61K38/00C07K14/475C07K2319/00A61P9/00A61P35/00A61P43/00
Inventor GILL, PARKASH S.
Owner UNIV OF SOUTHERN CALIFORNIA